What is the recommended treatment for uncomplicated malaria in an adult?

Treatment for Uncomplicated Malaria in Adults

For uncomplicated malaria in adults, artemisinin-based combination therapy (ACT) is the treatment of choice, with artemether-lumefantrine (AL) being the preferred first-line agent in most settings. However, recent evidence suggests extending the standard 3-day course to 5 days (10 doses) for P. falciparum malaria in travelers to improve treatment success 1.

Treatment Algorithm by Species and Resistance Pattern

For Uncomplicated P. falciparum Malaria

First-line treatment:

• Artemether-lumefantrine (AL): Extended 5-day (10-dose) regimen is now recommended based on 2026 CDC guidance 1
  • This addresses increasing treatment failures with the standard 3-day course, particularly in travelers returning from Africa
  • 85% of AL failures were late recrudescences occurring 1-8 weeks after initial treatment
  • Treatment failure risk has increased to 7% for data collected after 2018 compared to 4% before 2018 1

Alternative ACTs:

• Dihydroartemisinin-piperaquine (Eurartesim®) 2, 3

Second-line options (when ACTs contraindicated or for Southeast Asian travel with ACT resistance):

• Atovaquone-proguanil (Malarone®) 2, 3
• Quinine sulfate plus doxycycline (or clindamycin if doxycycline contraindicated) 2, 3

For Uncomplicated Non-Falciparum Malaria (P. vivax, P. ovale, P. malariae)

In chloroquine-sensitive areas:

• Chloroquine: Total dose of 1,500 mg (25 mg/kg) over 3 days 4
  • Day 0: 600 mg
  • Day 1: 600 mg
  • Day 2: 300 mg

In chloroquine-resistant areas (Papua New Guinea, Indonesia, Sabah):

• ACTs preferred, particularly dihydroartemisinin-piperaquine which shows superior efficacy over chloroquine or AL for P. vivax 2

Critical addition for P. vivax and P. ovale:

• Primaquine for hypnozoite eradication: 15 mg daily for 14 days 4, 2
  • Must test for G6PD deficiency before administration - primaquine causes severe hemolysis in G6PD-deficient patients 4, 2, 3
  • For mild-moderate G6PD deficiency (30-70% activity): 45 mg once weekly for 8 weeks 2
  • Contraindicated in pregnancy and breastfeeding 3
  • More effective when given concurrently with chloroquine 3

Special Populations

Pregnancy

Second and third trimesters:

• Artemether-lumefantrine is now recommended based on 2018 CDC updated guidance demonstrating safety and efficacy 5, 3

First trimester:

• AL can be used when other options unavailable 5
• Traditional approach: Quinine plus clindamycin (seek specialist advice) 3

Important caveat: Pregnant women with malaria should be treated aggressively as infection carries increased risk for maternal and fetal complications 5, 4

Children

• ACTs (artemether-lumefantrine or dihydroartemisinin-piperaquine) are first-line 3
• Chloroquine dosing for non-falciparum: 25 mg/kg total over 3 days (10 mg/kg, 10 mg/kg, 5 mg/kg at 0,24,48 hours) 4
• Doxycycline should not be given to children under 12 years 3

Critical Monitoring and Follow-up

Post-Artemisinin Delayed Hemolysis (PADH)

• Occurs in up to 37% of patients treated with ACTs using strict definitions 2
• Check hemoglobin approximately 14 days after treatment with IV or oral artemisinins 2, 3
• Most serious adverse event associated with ACTs 2

Treatment Failure Surveillance

• Patients remaining symptomatic beyond 3 days require repeat thick smear 4
• Alternative therapy should be instituted if parasitemia has not diminished markedly 4
• Consider extended AL regimen or alternative agent if standard course fails 1

Common Pitfalls to Avoid

1. Don't assume standard 3-day AL is sufficient for travelers: Recent data shows increasing failures, particularly with late recrudescence 1

2. Don't forget G6PD testing before primaquine: This is non-negotiable for P. vivax and P. ovale to prevent life-threatening hemolysis 4, 2, 3

3. Don't use primaquine in pregnancy: Use weekly chloroquine prophylaxis until delivery, then treat hypnozoites postpartum 3

4. Don't ignore geographic resistance patterns: Southeast Asian malaria may require atovaquone-proguanil instead of ACTs due to artemisinin resistance 2, 6

5. Don't forget that body weight affects lumefantrine levels: Lower weight patients may have subtherapeutic concentrations, supporting extended regimens 2

6. Don't discharge too early: Most patients should be admitted for at least 24 hours as deterioration can occur suddenly, especially early in treatment 3